Benefits of Lu-177 PSMA Therapy
Highly Targeted Treatment
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, Lu-177 PSMA therapy selectively targets prostate cancer cells expressing PSMA.
This targeted mechanism helps preserve healthy tissues while delivering effective treatment directly to cancer cells.
Conditions Treated with Lu-177 PSMA Therapy
Lu-177 PSMA therapy is primarily used for:
-
Metastatic castration-resistant prostate cancer (mCRPC)
-
Progressive metastatic prostate cancer
-
Recurrent prostate cancer with widespread disease
-
PSMA-positive prostate cancer following failure of conventional therapies
The treatment is not intended for every patient with prostate cancer. Eligibility is determined through careful clinical evaluation and specialized imaging.
The Importance of PSMA PET/CT Before Treatment
A PSMA PET/CT scan is an essential step before Lu-177 PSMA therapy.
This advanced imaging examination determines:
-
Whether prostate cancer cells express PSMA
-
The location of cancer throughout the body
-
The extent of metastatic disease
-
Whether sufficient PSMA expression exists for effective treatment
Patients whose tumors demonstrate strong PSMA uptake are generally the best candidates for radioligand therapy.
In this way, molecular imaging serves as a companion diagnostic, ensuring that treatment is personalized for each patient.
Who May Benefit from Lu-177 PSMA Therapy?
Lu-177 PSMA therapy is generally recommended for patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed despite conventional treatments.
Candidates often include patients who have received one or more of the following:
-
Androgen deprivation therapy (ADT)
-
Novel hormonal therapies
-
Chemotherapy
-
Radiation therapy
-
Surgery
-
Other systemic treatments
The decision to proceed with Lu-177 PSMA therapy is made by a multidisciplinary team that may include nuclear medicine physicians, medical oncologists, urologists, radiation oncologists, and radiologists.
Each patient's medical history, laboratory results, imaging studies, and overall health are carefully evaluated before treatment.
How Does Lu-177 PSMA Therapy Work?
Lu-177 PSMA therapy works through a highly targeted process.
After intravenous administration, the radioligand circulates throughout the bloodstream until it encounters prostate cancer cells expressing PSMA.
The targeting molecule attaches specifically to these cells and is absorbed into the cancer tissue.
Once bound, the Lutetium-177 emits beta particles that travel only a short distance within the surrounding tissue.
These beta particles damage the DNA of nearby cancer cells, preventing them from dividing and causing many of them to die.
Because the radiation travels only a few millimeters, nearby healthy tissues receive significantly less radiation than the cancer itself.
This targeted approach allows treatment of cancer throughout the body while reducing many of the side effects associated with conventional systemic therapies.
Understanding PSMA
Prostate-Specific Membrane Antigen (PSMA) is a protein naturally found on prostate cells.
In most prostate cancers—particularly aggressive, metastatic, or recurrent disease—PSMA is present in much higher concentrations than in normal tissues.
This makes PSMA an ideal biological target for both diagnosis and treatment.
Before Lu-177 PSMA therapy is considered, patients typically undergo a PSMA PET/CT scan to determine whether their cancer expresses sufficient PSMA. Only patients whose tumors demonstrate adequate PSMA uptake are generally considered suitable candidates for treatment.
This personalized approach ensures that therapy is directed toward patients who are most likely to benefit.
What is Lu-177 PSMA Therapy?
Lu-177 PSMA Therapy is a form of Targeted Radioligand Therapy (RLT) specifically designed to treat prostate cancer that expresses Prostate-Specific Membrane Antigen (PSMA).
The treatment combines two essential components:
-
A molecule that specifically binds to PSMA receptors found on prostate cancer cells.
-
The therapeutic radioisotope Lutetium-177 (Lu-177), which emits beta radiation capable of destroying cancer cells.
Once injected into the bloodstream, the PSMA-targeting molecule seeks out prostate cancer cells throughout the body. After binding to these cells, the attached Lu-177 delivers localized radiation that damages the cancer cells while minimizing radiation exposure to surrounding normal tissues.
This highly selective mechanism allows physicians to treat cancer cells that may be present in multiple locations, including those too small to be removed surgically or treated with conventional radiation therapy.
A New Era in Precision Cancer Treatment
The treatment of prostate cancer has evolved significantly over the past decade, with advances in precision medicine providing new hope for patients with advanced disease. While surgery, radiation therapy, hormone therapy, chemotherapy, and newer hormonal agents remain the foundation of prostate cancer treatment, some patients eventually develop disease that continues to progress despite these therapies.
For these patients, Lutetium-177 Prostate-Specific Membrane Antigen (Lu-177 PSMA) Therapy offers a highly targeted treatment approach that combines the precision of molecular imaging with the therapeutic power of radiation.
Unlike conventional radiation therapy, which delivers radiation from outside the body, Lu-177 PSMA therapy delivers radiation directly to prostate cancer cells wherever they are located. This innovative treatment selectively targets cancer cells while minimizing damage to surrounding healthy tissues.
Often described as "theranostics"—a combination of therapy and diagnostics—Lu-177 PSMA therapy represents one of the most significant advances in nuclear medicine and precision oncology, offering new treatment opportunities for patients with advanced prostate cancer.